Regencell Bioscience (NASDAQ:RGC) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Regencell Bioscience (NASDAQ:RGC) from a hold rating to a sell rating in a report released on Saturday morning.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Regencell Bioscience Stock Up 1.6%

NASDAQ:RGC opened at $5.10 on Friday. Regencell Bioscience has a fifty-two week low of $4.51 and a fifty-two week high of $69.00. The stock’s 50-day moving average is $15.81 and its two-hundred day moving average is $24.01.

Regencell Bioscience (NASDAQ:RGC) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.00) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Seven Fleet Capital Management LP purchased a new stake in shares of Regencell Bioscience during the 4th quarter worth about $92,000. Amundi bought a new stake in shares of Regencell Bioscience in the 1st quarter valued at approximately $219,000. Hudson Bay Capital Management LP bought a new stake in shares of Regencell Bioscience in the 4th quarter valued at approximately $275,000. Bank of America Corp DE grew its stake in shares of Regencell Bioscience by 59,113.8% in the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after buying an additional 17,143 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in Regencell Bioscience in the third quarter worth approximately $598,000. 0.13% of the stock is owned by institutional investors and hedge funds.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.